natgillin/translations-raw huggingface dataset:
The EU financial contribution to the IMI 2 Joint Undertaking under Horizon 2020 will be up to 1,638 billion euro, of which up to 1,425 billion to match the contribution7 of the pharmaceutical sector and up to 213 million to match contributions from other companies that decide to join IMI 2 as Associated Partners. 
EU:s finansiella bidrag till det gemensamma fretaget IMI genom Horisont 2020 ska uppg till hgst 1,638 miljarder euro, varav upp till 1,425 miljarder euro motsvarande bidraget7 frn lkemedelssektorn och upp till 213 miljoner euro motsvarande ytterligare bidrag frn andra fretag som beslutar att g med i det gemensamma fretaget IMI 2 som associerade partner.
The Members are to contribute equally to the running costs (which should not exceed 85,2 million euro for the IMI 2 Joint Undertaking). 
Medlemmarnas bidrag till de lpande kostnaderna (som inte fr verstiga 85,2 miljoner euro fr det gemensamma fretaget IMI 2) ska frdelas jmnt.
6 7 The Annex summarises the Joint UndertakingŐs competences, activities and available resources. 
6 7 I bilagan sammanfattas det gemensamma fretagets behrighet, verksamhet och tillgngliga resurser i informationssyfte.
It is presented for information purposes. Article 13(3) of the Annex to Regulation (EU) No 557/2014 stipulates that the Ňoperational costs of the IMI 2 Joint Undertaking shall be covered through (a) a financial contribution by the Union (b) in-kind contributions by the Members other than the Union and the Associated Partners [...] consisting of the costs incurred by them in implementing indirect actions [...] less the contribution of the IMI 2 Joint Undertaking and any other Union contribution to those costsÓ. 
4 I artikel 13.3 i bilagan till frordning (EU) nr 557/2014 freskrivs att "driftskostnaderna fr det gemensamma fretaget IMI 2 ska tckas genom fljande bidrag: a) Ett finansiellt bidrag frn unionen. b) Bidrag in natura frn de andra medlemmarna n unionen och frn de associerade partnerna [...] bestende av de kostnader som dessa drar sig vid genomfrandet av indirekta tgrder [...] minus det gemensamma fretaget IMI 2:s och andra finansiella bidrag frn unionen till de kostnaderna".
AEI059801EN04-15PP-CH143-15APCFIN-RAS-IMI-OR.docx 6.10.2015 STATEMENT OF ASSURANCE 6. 
AEI059801SV04-15PP-CH143-15APCFIN-RAS-IMI-TR.docx 6.10.2015 REVISIONSF RKLARING 6.
Pursuant to the provisions of Article 287 of the Treaty on the Functioning of the European Union (TFEU), the Court has audited: (a) the annual accounts of the IMI Joint Undertaking, which comprise the financial statements8 and the reports on the implementation of the budget9 for the financial year ended 31 December 2014, and (b) the legality and regularity of the transactions underlying those accounts. 
Revisionsrtten har i enlighet med artikel 287 i frdraget om Europeiska unionens funktionsstt granskat a) det gemensamma fretaget IMI:s rsredovisning, som bestr av rkenskaperna8 och rapporterna om budgetgenomfrandet9 fr det budgetr som slutade den 31 december 2014, b) lagligheten och korrektheten i de transaktioner som ligger till grund fr rkenskaperna.
The management's responsibility 7. 
Ledningens ansvar 7.
In accordance with Articles 16 and 22 of Commission Delegated Regulation (EU) No 110/201410, the management is responsible for the preparation and fair presentation of the annual accounts of the Joint Undertaking and the legality and regularity of the underlying transactions. (a) The managementŐs responsibilities in respect of the Joint UndertakingŐs annual accounts include designing, implementing and maintaining an internal control system relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error, selecting and applying appropriate accounting policies on the basis of the accounting rules adopted by the CommissionŐs accounting officer11, and making accounting estimates that are reasonable in the circumstances. 
I enlighet med artiklarna 16 och 22 i kommissionens delegerade frordning (EU, Euratom) nr 110/201410 r det ledningen som har ansvaret fr att upprtta en rsredovisning fr det gemensamma fretaget som ger en rttvisande bild och fr att de underliggande transaktionerna r lagliga och korrekta. a) I ledningens ansvar fr det gemensamma fretagets rsredovisning ingr att utforma, infra och upprtthlla de system fr internkontroll som krvs fr upprttandet av rkenskaper som ger en rttvisande bild och som inte innehller vsentliga felaktigheter, vare sig dessa beror p oegentligheter eller fel, vlja och tillmpa ndamlsenliga redovisningsprinciper utifrn de redovisningsregler som antagits av kommissionens rkenskapsfrare11 och gra uppskattningar i redovisningen som r rimliga med hnsyn till omstndigheterna.
The Director approves the annual accounts of the Joint Undertaking after its accounting officer has prepared them on the basis of all available information and established a note to accompany the accounts in which he declares, 8 9 10 11. 
Direktren godknner det gemensamma fretagets rsredovisning efter det att rkenskapsfraren har upprttat den p grundval av all tillgnglig information tillsammans med en not till rsredovisningen dr han eller 8 9 10 11.
5 These include the balance sheet and the statement of financial performance, the cash-flow table, the statement of changes in net assets, a summary of the significant accounting policies and other explanatory notes. 
5 Hr ingr balans-och resultatrkningen, kassafldesanalysen, sammanstllningen av frndringar i nettotillgngarna och en sammanfattning av de viktigaste redovisningsprinciperna och andra frklarande noter.
The accounting rules adopted by the CommissionŐs accounting officer are derived from the International Public Sector Accounting Standards (IPSAS) issued by the International Federation of Accountants or, where relevant, the International Accounting Standards (IAS)/International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board. AEI059801EN04-15PP-CH143-15APCFIN-RAS-IMI-OR.docx 6.10.2015 
De redovisningsregler som antagits av kommissionens rkenskapsfrare bygger p de internationella redovisningsstandarderna fr den offentliga sektorn (Ipsas) som ges ut av Internationella revisorsfrbundet IFAC eller, nr s r lmpligt, p de internationella redovisningsstandarderna International Accounting Standards (IAS)/International Financial Reporting Standards (IFRS) som ges ut av International Accounting Standards Board (IASB). AEI059801SV04-15PP-CH143-15APCFIN-RAS-IMI-TR.docx 6.10.2015
inter alia, that he has reasonable assurance that they present a true and fair view of the financial position of the Joint Undertaking in all material respects. (b) The managementŐs responsibilities in respect of the legality and regularity of the underlying transactions and compliance with the principle of sound financial management consist of designing, implementing and maintaining an effective and efficient internal control system comprising adequate supervision and appropriate measures to prevent irregularities and fraud and, if necessary, legal proceedings to recover funds wrongly paid or used. 
hon bland annat frklarar att han eller hon har uppntt rimlig skerhet om att den ger en i alla vsentliga avseenden sann och rttvisande bild av det gemensamma fretagets finansiella stllning. b) Ledningens ansvar nr det gller de underliggande transaktionernas laglighet och korrekthet och efterlevnaden av principen om sund ekonomisk frvaltning bestr i att utforma, infra och upprtthlla ett ndamlsenligt och effektivt system fr internkontroll som innefattar en tillfredsstllande vervakning och lmpliga tgrder fr att frebygga oriktigheter och oegentligheter och, vid behov, rttsliga frfaranden fr att krva tillbaka belopp som betalats ut eller anvnts felaktigt.
The CourtŐs responsibility is, on the basis of its audit, to provide the European Parliament and the Council12 with a statement of assurance as to the reliability of the annual accounts and the legality and regularity of the underlying transactions. 
Revisionsrtten ska utifrn revisionen avge en frklaring till Europaparlamentet och rdet12 om rsredovisningens tillfrlitlighet och de underliggande transaktionernas laglighet och korrekthet.
The audit also entails evaluating the appropriateness of accounting policies, the reasonableness of accounting estimates and the overall presentation of the accounts. 
ndamlsenlighet, rimligheten i uppskattningarna i redovisningen och den vergripande presentationen i rkenskaperna.
COMMENTS ON BUDGETARY AND FINANCIAL MANAGEMENT Implementation of the budget 14. 
KOMMENTARER OM BUDGETF RVALTNINGEN OCH DEN EKONOMISKA F RVALTNINGEN Budgetgenomfrandet 14.
The 2014 budget included commitment appropriations amounting to 223 million euro and payment appropriations amounting to 171 million euro. 
Budgeten fr 2014 innehll tagandebemyndiganden p 223 miljoner euro och betalningsbemyndiganden p 171 miljoner euro.
The overall implementation rate was 92,4 % (99,5 % for 2013) for commitment appropriations and 73,9 % (97,5 % for 2013) for payment appropriations. 
Den vergripande genomfrandegraden var 92,4 % (99,5 % r 2013) fr tagandebemyndigandena och 73,9 % (97,5 % r 2013) fr betalningsbemyndigandena.
In the case of operational activities, the implementation rate was 93 % for commitment appropriations and 74 % for payment appropriations13. 
Nr det gller driftsverksamheten var genomfrandegraden 93 % fr tagandebemyndiganden och 74 % fr betalningsbemyndiganden13.
However, commitment appropriations were committed at a global level, meaning that no corresponding grant agreements have been signed by the end of 2014. 
Emellertid gjordes tagandebemyndigandena p global niv, vilket innebr att motsvarande bidragsverenskommelser inte hade undertecknats vid utgngen av 2014.
The FP7 calls for proposals organised in 2008 - 2013 resulted in grant agreements totalling 897 million euro, amounting to 93 % of the maximum EU contribution to the Joint Undertaking for research activities. 
De anskningsomgngar som organiserades inom sjunde ramprogrammet 2008Đ2013 ledde till bidragsverenskommelser p totalt 897 miljoner euro, vilket motsvarar 93 % av det maximala EU-bidraget till det gemensamma fretaget fr forskningsverksamhet. VRIGT Nyckelkontroller och vervakningssystem 17.
As regards administrative expenditure, the appropriations available for 2014 amounted to 8,9 million euro. 
13 8 Nr det gller administrativa utgifter uppgick de tillgngliga anslagen fr 2014 till 8,9 miljoner euro.
The IMI Joint Undertaking achieved an implementation rate of 84 % for commitment appropriations and 70 % for payment appropriations. AEI059801EN04-15PP-CH143-15APCFIN-RAS-IMI-OR.docx 6.10.2015 
Det gemensamma fretaget IMI uppndde en genomfrandegrad p 84 % fr tagandebemyndiganden och 70 % fr betalningsbemyndiganden. AEI059801SV04-15PP-CH143-15APCFIN-RAS-IMI-TR.docx 6.10.2015
The financial rules of the IMI 2 Joint Undertaking were adopted on 7 July 2014 on the basis of the model financial regulation for public-private partnership bodies14 and taking into account the requirements of Council Regulation (EU) 557/2014 establishing the IMI 2 Joint Undertaking. 
De finansiella reglerna fr det gemensamma fretaget IMI antogs den 7 juli 2014 och baserades p modellbudgetfrordningen fr offentlig-privata partnerskap14 och beaktade kraven i rdets frordning (EU) nr 557/2014 om bildande av det gemensamma fretaget IMI 2.
Internal audit function and the CommissionŐs Internal Audit Service 19. 
Internrevisionsfunktionen och kommissionens tjnst fr internrevision 19.
In January 2014, the CommissionŐs Internal Audit Service (IAS) finalised an audit on project monitoring and the reporting of operational performance at the IMI Joint Undertaking. 
I januari 2014 slutfrde kommissionens tjnst fr internrevision en revision om projektvervakning och rapporteringen om verksamhetens resultat vid det gemensamma fretaget IMI.
As at April 2015, all recommendations have been addressed through agreed actions15. 
I april 2015 hade alla rekommendationer genomfrts genom verenskomna tgrder15.
The IAS is monitoring the implementation of the action plan and an assessment is expected during 2015 with regard to closing the recommendations. 
Tjnsten fr internrevision vervakar genomfrandet av handlingsplanen, och en bedmning frvntas under 2015 infr en avslutning av rekommendationerna.
In addition, two audits were completed in early 2015, one on ex ante controls for operational expenditure and the other on risk assessment. 
Vidare slutfrdes tv revisioner i brjan av 2015, en om frhandskontroller av driftsutgifter och en annan om riskbedmning.
The IMI Joint Undertaking has addressed the recommendation on ex ante controls through an action plan that has been accepted by the IAS. 
Det gemensamma fretaget IMI har genomfrt rekommendationen om frhandskontroller genom en handlingsplan som tjnsten fr internrevision har godtagit.
FOLLOW-UP OF PREVIOUS OBSERVATIONS Monitoring and reporting of project research results 21. 
UPPF LJNING AV TIDIGARE IAKTTAGELSER vervakning och rapportering av forskningsresultat 21.
As regards the monitoring and reporting of project research results16, the IMI Joint Undertaking uses its own tools, in order to integrate its research results into the overall reporting system of the Commission. 
Nr det gller vervakningen och rapporteringen av resultaten av forskningsprojekt16 anvnder det gemensamma fretaget IMI sina egna verktyg fr att integrera sina forskningsresultat i kommissionens vergripande rapporteringssystem.
For the first time, the latest Monitoring report from the Commission on FP7, published in March 201517, includes quantitative data from IMI Joint Undertaking activities18. 
9 AEI059801SV04-15PP-CH143-15APCFIN-RAS-IMI-TR.docx 6.10.2015 offentliggjordes i mars 201517, kvantitativa uppgifter frn det gemensamma fretaget IMI:s verksamheter18.
As regards qualitative data, in addition to the information provided on the IMI website, the Joint Undertaking produces a half yearly bibliometric analysis of ongoing projects19, aiming to benchmark research published by IMI-supported projects with other selected public private partnerships. 
Vad betrffar kvalitativa uppgifter producerar det gemensamma fretaget, utver den information som finns p IMI:s webbplats, var sjtte mnad en bibliometrisk analys av pgende projekt19, dr syftet r att riktmrka forskningsresultat som publiceras av IMI-stdda projekt med andra utvalda offentlig-privata partnerskap.
The IMI Joint Undertaking has also developed key performance indicators for the various aspects of project achievement and it measures progress on this basis. 
Det gemensamma fretaget IMI har ocks tagit fram centrala resultatindikatorer fr de olika aspekterna av projektresultat och mter framsteg utifrn detta.
The Horizon 2020 legal framework requires specific monitoring of research results, based on quantitative and, where appropriate, qualitative evidence, including progress against performance indicators20. 
Den rttsliga ramen fr Horisont 2020 anger att forskningsresultat srskilt ska vervakas utifrn kvantitativa och, nr det r lmpligt, kvalitativa bevis, bland annat nr det gller framsteg i frhllande till resultatindikatorer20.
contribute to the dissemination of FP7 research results, cooperation between the Joint Undertaking and the Commission must be developed as much as possible21 with special regard to the further integration of IMI Joint Undertaking data in to the CommissionŐs systems. 
Fr att uppfylla kraven i Horisont 2020 och bidra bttre till spridningen av forskningsresultat inom sjunde ramprogrammet br samarbetet mellan det gemensamma fretaget och kommissionen utvecklas s mycket som mjligt21, srskilt med tanke p en ytterligare integrering av uppgifter frn det gemensamma fretaget IMI i kommissionens system.
The CommissionŐs Second Interim Evaluation 24. 
Kommissionens andra interimsutvrdering 24.
The recommendations of the CommissionŐs Second Interim Evaluation were presented to the Governing Board on 29 October 2013. 
Rekommendationerna frn kommissionens andra interimsutvrdering presenterades fr styrelsen den 29 oktober 2013.
Follow up of the recommendation was proposed and some key actions22 were integrated into the 2014 Annual Implementation Plan. 
En uppfljning av rekommendationen freslogs, och vissa nyckeltgrder22 integrerades i den rliga genomfrandeplanen fr 2014.
The Executive Director has reported regularly to the Governing Board on the follow-up of the actions. 
Den verkstllande direktren har rapporterat regelbundet till styrelsen om hur tgrderna fljs upp.
Recommendations related to the establishment of the IMI2 JU23 are currently being implemented and plans are in place for the Programme Office to carry out consolidated follow-up and assessment of the actions undertaken by the end of 2015. 
Rekommendationer som gller bildandet av det gemensamma fretaget IMI 223 genomfrs fr nrvarande och det finns planer p att programkontoret ska gra en konsoliderad uppfljning och bedmning av de tgrder som vidtagits fre utgngen av 2015.
E.g. review of the Communication Strategy, socio-economic impacts translated within KPIs, further involvement of industry and in particular of SMEs, increasing flexibility in launching calls and use of non-EU in-kind contribution. 
22 23 Till exempel versyn av kommunikationsstrategin, socioekonomiska effekter som versatts inom centrala resultatindikatorer, ytterligare medverkan av industrin och srskilt sm och medelstora fretag, kad flexibilitet nr det gller att inleda anbudsfrfaranden och anvndning av bidrag in natura frn de andra medlemmarna n EU.
E.g. involvement of industrial participants from other healthcare related sector, increased flexibility and transparency in terms of governance. 
Till exempel medverkan av deltagare frn industrin frn andra hlso-och sjukvrdsrelaterade sektorer, kad flexibilitet och ppenhet nr det gller frvaltning.
For the Court of Auditors Vtor Manuel da SILVA CALDEIRA President 11 AEI059801EN04-15PP-CH143-15APCFIN-RAS-IMI-OR.docx 6.10.2015 
Fr revisionsrtten Vtor Manuel da SILVA CALDEIRA ordfrande 11 AEI059801SV04-15PP-CH143-15APCFIN-RAS-IMI-TR.docx 6.10.2015
Innovative Medicines Joint Undertaking (Brussels) Competences and activities Annex 1 Areas of Union competence deriving from the Treaty Extracts from Articles 187 and 188 of the Treaty on the Functioning of the European Union Competences of the Joint Undertaking Council Regulation (EU) No 557/2014 of 6 May 2014 establishing the Innovative Medicines Initiative 2 Joint Undertaking (OJ L 169, 7.6.2014, p. 
Det gemensamma fretaget fr innovativa lkemedel (Bryssel) Behrighet och verksamhet Bilaga 1 Unionens behrighetsomrde enligt frdraget utdrag frn artiklarna 187 och 188 i EUF-frdraget Det gemensamma fretagets behrighet rdets frordning (EU) nr 557/2014 av den 6 maj 2014 om bildande av det gemensamma fretaget fr initiativet fr innovativa lkemedel 2 (EUT L 169, 7.6.2014, s.
54) The Union may set up joint undertakings or any other structure necessary for the efficient execution of Union research, technological development and demonstration programmes. 
54) Unionen kan bilda gemensamma fretag eller andra organisationer som krvs fr att effektivt genomfra unionens program fr forskning, teknisk utveckling och demonstration.
The Council, on a proposal from the Commission and after consulting the European Parliament and the Economic and Social Committee, shall adopt the provisions referred to in Article 187. 
Rdet ska, p frslag av kommissionen och efter att ha hrt Europaparlamentet och Ekonomiska och sociala kommittn, anta de bestmmelser som avses i artikel 187.
The European Parliament and the Council, acting in accordance with the ordinary legislative procedure and after consulting the Economic and Social Committee, shall adopt the provisions referred to in Articles 183, 184 and 185. 
Europaparlamentet och rdet ska i enlighet med det ordinarie lagstiftningsfrfarandet och efter att ha hrt Ekonomiska och sociala kommittn anta de bestmmelser som avses i artiklarna 183, 184 och 185.
Adoption of the supplementary programmes shall require the agreement of the Member States concerned. 
Antagandet av tillggsprogrammen krver de berrda medlemsstaternas samtycke.
Objectives According to Article 2 of Council Regulation 557/2014 the IMI2 Joint Undertaking shall have the following objectives: (a) to support, in accordance with Article 25 of Regulation (EU) No 1291/2013, the development and implementation of precompetitive research and of innovation activities of strategic importance to the UnionŐs competitiveness and industrial leadership or to address specific societal challenges in particular as described in parts II and III of Annex I to Decision 2013/743/EU, and in particular the challenge to improve European citizensŐ health and well-being; (b) to contribute to the objectives of the Joint Technology Initiative on Innovative Medicines, in particular to: (i) increase the success rate in clinical trials of priority medicines identified by the World Health Organisation; (ii) where possible, reduce the time to reach clinical proof of concept in medicine development, such as for cancer, immunological, respiratory, neurological and neurodegenerative diseases; (iii) develop new therapies for diseases for which there is a high unmet need, such as AlzheimerŐs disease and limited market incentives, such as antimicrobial resistance; (iv) develop diagnostic and treatment biomarkers for diseases clearly linked to clinical relevance and approved by regulators; (v) reduce the failure rate of vaccine candidates in phase III clinical trials through new biomarkers for initial efficacy and safety checks; (vi) improve the current drug development process by providing support for the development of tools, standards and approaches to assess efficacy, safety and quality of regulated health products. Governance bodies of the IMI2 JU are (i) the Governing Board, (ii) the Executive Director, (iii) the Scientific Committee, (iv) the States Governance AEI059801EN04-15PP-CH143-15APCFIN-RAS-IMI-OR.docx 6.10.2015 
Ml Enligt artikel 2 i rdets frordning 557/2014 ska det gemensamma fretaget IMI 2 ha fljande ml: a) Att i enlighet med artikel 25 i frordning (EU) nr 1291/2013 stdja utvecklingen och genomfrandet av forskning fre det konkurrensutsatta stadiet och av innovationsverksamhet av strategisk betydelse fr unionens konkurrenskraft och industriella ledarskap eller fr hanteringen av srskilda samhllsutmaningar, srskilt som beskrivs i delarna II och III i bilaga I till beslut 2013/743/EU, och i synnerhet utmaningen att frbttra de europeiska medborgarnas hlsa och vlbefinnande. b) Att bidra till uppnendet av mlen fr det gemensamma teknikinitiativet fr innovativa lkemedel, i synnerhet fr att i) ka andelen framgngsrika kliniska prvningar av prioriterade lkemedel som identifierats av Vrldshlsoorganisationen, ii) dr det r mjligt minska tiden fram till kliniska koncepttest inom lkemedelsutveckling, t.ex. fr cancer samt immunologiska, respiratoriska, neurologiska och neurodegenerativa sjukdomar, iii) utveckla nya behandlingsmetoder fr sjukdomar fr vilka det finns ett omfattande icke tillgodosett behov (t.ex.
2 Resources available to the Joint Undertaking in 2014 Activities and services provided in 2014 Representatives Group, and (v) the Stakeholder Forum. Other advisory groups may be set up by the Governing Board. 
2 Organisation Det gemensamma fretaget IMI 2:s organ ska vara i) styrelsen, ii) verkstllande direktren, iii) vetenskapliga kommittn, iv) gruppen med staternas fretrdare och v) forumet fr intressenter.